INDV vs SUPN
INDV: A pharmaceutical company specialized in innovative treatments for substance use and mental health disorders. SUPN: Supernus Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing and selling specialized treatments for CNS disorders.
Side-by-side fundamentals
| Metric | INDV | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $34.77 | $41.23 | |
| Market cap as of 2026-07-28 (share count; price 2026-10-20) | $4.1B | $2.4B | |
| P/E as of 2026-10-20 | 12.46 | n/a | |
| Net margin FY2025, SEC XBRL | +16.9% | -5.4% | INDV higher |
| Gross margin FY2025, SEC XBRL | +80.2% | n/a | |
| Operating margin FY2025, SEC XBRL | +21.1% | -8.7% | INDV higher |
| ROE FY2025, SEC XBRL | n/a | -3.6% | |
| ROA FY2025, SEC XBRL | +17.5% | -2.7% | INDV higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +4.3% | +8.6% | SUPN higher |
| Revenue CAGR (3y) SEC XBRL | +11.2% | +2.5% | INDV higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-02 | 0.77 | 0.52 | |
| 1-year return as of 2026-10-20 close | +43.1% | -20.1% | INDV higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.